Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2026 –2033 | |
|
|
USD 2.23 Million |
| USD 3.03 Million | |
| % | |
|
Middle East and Africa Immunoassay-Gamma Counters Market Segmentation, By Product Type (Automated and Manual/ Semi-Automated), Well (Multi-well and Single-well), Application (Radio Immunoassays, Nuclear Medicine Assays, and Others), Disease Condition (Cancer Biomarker, Infectious Diseases, Therapeutic Drug Monitoring, Endocrine Hormones, Allergy, Neonatal Screening, Cardiac Markers, Auto Immune Disease, and Others), Purchase Mode (Out-right Purchase and Rental Purchase), End User (Laboratory, Hospitals, Research & Academic Institutes, Pharmaceutical & Biotechnology Companies, Blood banks, and Others), Distribution Channel (Direct Tender, and Third Party Distributors)- Industry Trends and Forecast to 2033
Get Exclusive Sample Copy of this Report Here
|
Attributes
|
Middle East and Africa Immunoassay-Gamma Counters Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
Middle East and Africa
|
|
Key Market Players
|
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Enhanced Accuracy Through Automation and Connectivity
Driver
Increasing Healthcare Investments and Diagnostic Needs
Restraint/Challenge
High Costs and Skilled Workforce Requirement
The market is segmented on the basis of product type, well, application, disease condition, purchase mode, end user, and distribution channel.
On the basis of product type, the market is segmented into automated and manual/semi-automated. The automated segment dominated the market with the largest revenue share of 52.9% in 2025, driven by its high throughput, reduced human error, and ability to integrate into existing laboratory workflows. Laboratories across Egypt, South Africa, and UAE prefer automated gamma counters for faster processing of multiple samples and consistent assay results. They also support LIMS integration and AI-assisted analysis, enhancing data accuracy and compliance. Automated counters minimize manual intervention, save operational time, and allow centralized monitoring of multiple assays. The segment benefits from ongoing technological advancements, predictive maintenance features, and improved sample handling. Overall, automated systems are increasingly becoming standard equipment in hospitals, research labs, and academic institutes.
The manual/semi-automated segment is anticipated to witness the fastest growth at a CAGR of 8.5% from 2025 to 2033, driven by smaller laboratories and emerging markets seeking cost-effective alternatives to automated systems. Manual counters require less capital investment, making them accessible to budget-constrained facilities. They are also easier to maintain, train staff on, and deploy in laboratories with limited infrastructure. Their simplicity and operational flexibility suit private clinics and mobile testing units. In addition, rising awareness about gamma counter capabilities in smaller labs is boosting adoption. As emerging MEA countries expand diagnostic services, demand for manual and semi-automated counters continues to grow steadily.
On the basis of well, the market is segmented into multi-well and single-well gamma counters. The multi-well segment dominated the market in 2025 with a revenue share of 58%, supported by its ability to process multiple samples simultaneously, enhancing laboratory efficiency. Multi-well counters are widely used in hospitals and research institutes with high sample volumes. They ensure consistent assay conditions, reduce variability, and improve reliability of results. Integration with automated workflows and LIMS further increases throughput and operational efficiency. Multi-well counters also reduce staff workload, saving time and improving laboratory productivity. The segment continues to benefit from growing investments in high-volume diagnostic facilities.
The single-well segment is expected to witness the fastest growth at 9.1% CAGR from 2025 to 2033, driven by adoption in smaller laboratories, specialty clinics, and mobile testing facilities. Single-well counters are suitable for low-volume assays and specialized tests requiring precise measurements. Their portability, simplicity, and lower operational requirements make them attractive for emerging laboratories. Adoption is growing in UAE, Morocco, and Kenya where small-scale laboratories seek reliable solutions. The single-well segment is also benefiting from affordable models that provide high accuracy without heavy investment. Training requirements are minimal, encouraging further uptake.
On the basis of application, the market is segmented into radioimmunoassays, nuclear medicine assays, and others. The radioimmunoassay (RIA) segment dominated with the largest revenue share of 54% in 2025, due to its widespread use in hormone analysis, drug monitoring, and infectious disease diagnostics. Hospitals and research laboratories prefer RIA for its sensitivity and ability to quantify low-concentration analytes. Automated gamma counters enhance workflow efficiency and reduce human error in RIA testing. The segment benefits from government and private healthcare initiatives that expand diagnostic capabilities. High adoption in academic and clinical research settings further reinforces its dominant position.
The nuclear medicine assay segment is expected to witness the fastest growth at 8.8% CAGR from 2025 to 2033, driven by expanding nuclear medicine departments and increasing radiopharmaceutical use. Gamma counters capable of handling isotopes safely and efficiently are in demand in South Africa, Saudi Arabia, and UAE. Hospitals are investing in specialized labs for cancer diagnostics and therapy monitoring. The segment also benefits from rising awareness about personalized medicine. The integration of automated features improves precision and reduces staff exposure to radiation.
On the basis of disease condition, the market is segmented into cancer biomarkers, infectious diseases, therapeutic drug monitoring, endocrine hormones, allergy, neonatal screening, cardiac markers, autoimmune disease, and others. The infectious diseases segment dominated in 2025 with a revenue share of 30%, supported by rising prevalence of communicable diseases and government healthcare initiatives. Accurate diagnostic tools, such as gamma counters, are critical for outbreak monitoring and treatment planning. Adoption is high in hospitals, public health laboratories, and research institutions across MEA. Automated counters ensure fast, reliable testing and consistent results. Integration with LIMS enhances data reporting and regulatory compliance. The segment benefits from increasing awareness and demand for rapid diagnostics.
The cancer biomarkers segment is expected to register the fastest growth at 9.5% CAGR from 2025 to 2033, driven by rising cancer incidence and investments in oncology diagnostics. Automated gamma counters are preferred for precise biomarker quantification in hospitals and research labs. Countries such as Egypt, UAE, and South Africa are expanding oncology testing capabilities. Adoption is fueled by demand for early detection and personalized treatment. Integration with AI-assisted analysis further supports predictive diagnostics. Increasing collaborations with international diagnostic equipment providers are boosting growth.
On the basis of purchase mode, the market is segmented into out-right purchase and rental purchase. The out-right purchase segment dominated with a revenue share of 65% in 2025, driven by hospitals and research institutes preferring long-term ownership and control over maintenance. Immediate access, integration into workflows, and warranty benefits contribute to dominance. Large-scale laboratories benefit from cost-effectiveness in bulk procurement. Out-right purchase ensures availability for high-volume testing. Regulatory compliance and long-term reliability favor this segment.
The rental purchase segment is expected to witness the fastest growth at 10.2% CAGR from 2025 to 2033, fueled by small laboratories, mobile testing units, and startups seeking access to advanced gamma counters without high upfront costs. Flexible rental models allow access to the latest technology while minimizing capital expenditure. Training and support are often included in rental agreements. Smaller labs can perform high-quality assays without investing heavily. Emerging markets in UAE, Morocco, and Kenya are key adopters.
On the basis of end user, the market is segmented into laboratories, hospitals, research & academic institutes, pharmaceutical & biotechnology companies, blood banks, and others. The hospital segment dominated with a revenue share of 35% in 2025, due to high patient volumes, diagnostic demands, and integration of gamma counters into routine workflows. Multi-well automated counters are widely used for efficiency and regulatory compliance. Hospitals benefit from consistent, accurate results and improved workflow management. Investment in diagnostic infrastructure supports growth.
The research & academic institutes segment is expected to witness the fastest growth at 9% CAGR from 2025 to 2033, driven by rising funding for research, expansion of lab infrastructure, and adoption of gamma counters for advanced studies. Academic labs require precision for experimental assays and clinical research. Universities in Egypt, UAE, and South Africa are key adopters. Integration with automated features reduces error and improves reproducibility. Increasing collaborations with diagnostic equipment providers support segment growth.
On the basis of distribution channel, the market is segmented into direct tender and third-party distributors. The direct tender segment dominated with a revenue share of 60% in 2025, supported by government procurement programs and large institutions preferring cost-effective direct sourcing. Bulk purchases, warranties, and service contracts reinforce dominance. Hospitals and academic institutes often prefer direct tender for consistent supply and maintenance. Negotiation flexibility and service support are key advantages.
The third-party distributor segment is expected to witness the fastest growth at 8.7% CAGR from 2025 to 2033, driven by small clinics, private diagnostic labs, and emerging markets relying on distributors for access, training, and after-sales service. Local distributors provide support for installation, calibration, and troubleshooting. The segment facilitates adoption in regions with limited direct manufacturer presence. Private labs benefit from bundled service and training offerings. Expansion of distributor networks across MEA fuels growth in this segment.
The Egypt Immunoassay-Gamma Counters Market Insight
The Egypt immunoassay-gamma counters market captured the largest revenue share of 28% in 2025, driven by the presence of well-established medical research centers, government-funded healthcare programs, and a growing network of diagnostic laboratories. Hospitals and research institutions prioritize automated gamma counters for their accuracy, high throughput, and ability to integrate with laboratory information management systems (LIMS), ensuring operational efficiency and regulatory compliance. The growing prevalence of infectious and chronic diseases further increases demand for reliable diagnostic solutions. Moreover, collaborations with international diagnostic equipment manufacturers facilitate access to the latest technologies, supporting market expansion. Multi-well automated counters are particularly favored for high-volume testing in clinical and research settings. Rising investments in healthcare infrastructure continue to propel market growth.
South Africa Immunoassay-Gamma Counters Market Insight
The South Africa immunoassay-gamma counters market is anticipated to grow at a substantial CAGR during the forecast period, driven by advanced hospital networks, oncology and nuclear medicine facilities, and increasing adoption of high-sensitivity gamma counters for diagnostic testing. Government initiatives to strengthen healthcare infrastructure and funding for research laboratories are supporting market expansion. Hospitals and research centers value automated gamma counters for faster processing, accuracy, and integration with laboratory workflows. The multi-well segment sees strong demand due to high sample volumes. Increased awareness about advanced diagnostic technologies and collaboration with international equipment providers further stimulate growth. Both public and private healthcare institutions are investing in modern gamma counter systems.
United Arab Emirates Immunoassay-Gamma Counters Market Insight
The UAE immunoassay-gamma counters market is expected to grow at a noteworthy CAGR during the forecast period, fueled by rising healthcare expenditure, modernization of diagnostic laboratories, and increasing adoption of automated gamma counters. High patient volumes and the expansion of research and academic institutes are driving demand for reliable, high-throughput testing solutions. Hospitals and laboratories prefer multi-well automated systems for efficiency, accuracy, and regulatory compliance. Government-backed initiatives to enhance healthcare services encourage the acquisition of advanced diagnostic instruments. The UAE also benefits from partnerships with global diagnostic equipment providers, improving accessibility to the latest gamma counter technologies. Increasing focus on early disease detection and research supports market growth.
Saudi Arabia Immunoassay-Gamma Counters Market Insight
The Saudi Arabia immunoassay-gamma counters market is poised to grow at a considerable CAGR during the forecast period, driven by the expansion of oncology and nuclear medicine departments and rising demand for precision diagnostics. Hospitals and research institutions adopt automated gamma counters for high-volume testing, enhanced accuracy, and workflow integration. Government initiatives to improve healthcare infrastructure and the adoption of advanced diagnostic equipment facilitate market growth. Multi-well automated counters are increasingly preferred in both public and private healthcare facilities. The growing prevalence of infectious and chronic diseases further supports adoption. Partnerships with international manufacturers improve technology accessibility and local service support.
The Middle East and Africa Immunoassay-Gamma Counters industry is primarily led by well-established companies, including:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.